Matthew Anderson-Baron1,2, Yan Liang1,2, Melanie Kunze1,2, Aillette Mulet-Sierra1,2, Martin Osswald3,4, Khalid Ansari3, Hadi Seikaly3, Adetola B Adesida1,2,3. 1. Division of Orthopaedic Surgery, Department of Surgery, Faculty of Medicine and Dentistry, Laboratory of Stem Cell Biology and Orthopaedic Tissue Engineering, University of Alberta, Edmonton, AB, Canada. 2. Division of Surgical Research, Department of Surgery, Faculty of Medicine and Dentistry, Laboratory of Stem Cell Biology and Orthopaedic Tissue Engineering, University of Alberta, Edmonton, AB, Canada. 3. Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta Hospital, Edmonton, AB, Canada. 4. Institute for Reconstructive Sciences in Medicine, Misericordia Community Hospital, Edmonton, AB, Canada.
Abstract
OBJECTIVE: Human nasal septal chondrocytes (NC) are a promising minimally invasive derivable chondrogenic cell source for cartilage repair. However, the quality of NC-derived cartilage is variable between donors. Coculture of NC with mesenchymal stem cells (MSCs) mitigates the variability but with undesirable markers of chondrocyte hypertrophy, such as type X collagen, and the formation of unstable calcifying cartilage at ectopic sites. In contrast, monoculture NC forms non-calcifying stable cartilage. Formation of a stable NC-MSC coculture cartilage is crucial for clinical application. The aim of this study was to explore the utility of parathyroid hormone-related peptide (PTHrP) hormone to suppress chondrocyte hypertrophy in NC-MSC cocultures and form stable non-calcifying cartilage at ectopic sites. METHODS: Human NC and bone marrow MSCs, and cocultures of NC and MSC (1:3 ratio) were aggregated in pellet form and subjected to in vitro chondrogenesis for 3 weeks in chondrogenic medium in the presence and absence of PTHrP. Following in vitro chondrogenesis, the resulting pellets were implanted in immunodeficient athymic nude mice for 3 weeks. RESULTS: Coculture of NC and MSC resulted in synergistic cartilage matrix production. PTHrP suppressed the expression of hypertrophy marker, type X collagen (COL10A1), in a dose-dependent fashion without affecting the synergism in cartilage matrix synthesis, and in vivo calcification was eradicated with PTHrP. In contrast, cocultured control (CC) pellets without PTHrP treatment expressed COL10A1, calcified, and became vascularized in vivo.
OBJECTIVE: Human nasal septal chondrocytes (NC) are a promising minimally invasive derivable chondrogenic cell source for cartilage repair. However, the quality of NC-derived cartilage is variable between donors. Coculture of NC with mesenchymal stem cells (MSCs) mitigates the variability but with undesirable markers of chondrocyte hypertrophy, such as type X collagen, and the formation of unstable calcifying cartilage at ectopic sites. In contrast, monoculture NC forms non-calcifying stable cartilage. Formation of a stable NC-MSC coculture cartilage is crucial for clinical application. The aim of this study was to explore the utility of parathyroid hormone-related peptide (PTHrP) hormone to suppress chondrocyte hypertrophy in NC-MSC cocultures and form stable non-calcifying cartilage at ectopic sites. METHODS: Human NC and bone marrow MSCs, and cocultures of NC and MSC (1:3 ratio) were aggregated in pellet form and subjected to in vitro chondrogenesis for 3 weeks in chondrogenic medium in the presence and absence of PTHrP. Following in vitro chondrogenesis, the resulting pellets were implanted in immunodeficient athymic nude mice for 3 weeks. RESULTS: Coculture of NC and MSC resulted in synergistic cartilage matrix production. PTHrP suppressed the expression of hypertrophy marker, type X collagen (COL10A1), in a dose-dependent fashion without affecting the synergism in cartilage matrix synthesis, and in vivo calcification was eradicated with PTHrP. In contrast, cocultured control (CC) pellets without PTHrP treatment expressed COL10A1, calcified, and became vascularized in vivo.
Keywords:
cartilage; cocultures; human mesenchymal stem cells; human nasal chondrocytes; hypertrophic chondrogenesis; in vivo calcification; vascular invasion; xenograft
Authors: M E Cooke; A A Allon; T Cheng; A C Kuo; H T Kim; T P Vail; R S Marcucio; R A Schneider; J C Lotz; T Alliston Journal: Osteoarthritis Cartilage Date: 2011-07-23 Impact factor: 6.576
Authors: Nikolaos K Paschos; Wendy E Brown; Rajalakshmanan Eswaramoorthy; Jerry C Hu; Kyriacos A Athanasiou Journal: J Tissue Eng Regen Med Date: 2014-02-03 Impact factor: 3.963
Authors: Sylvain Provot; Hervé Kempf; L Charles Murtaugh; Ung-il Chung; Dae-Won Kim; Jay Chyung; Henry M Kronenberg; Andrew B Lassar Journal: Development Date: 2006-01-18 Impact factor: 6.868
Authors: C Candrian; D Vonwil; A Barbero; E Bonacina; S Miot; J Farhadi; D Wirz; S Dickinson; A Hollander; M Jakob; Z Li; M Alini; M Heberer; I Martin Journal: Arthritis Rheum Date: 2008-01
Authors: Ilario Fulco; Sylvie Miot; Martin D Haug; Andrea Barbero; Anke Wixmerten; Sandra Feliciano; Francine Wolf; Gernot Jundt; Anna Marsano; Jian Farhadi; Michael Heberer; Marcel Jakob; Dirk J Schaefer; Ivan Martin Journal: Lancet Date: 2014-04-10 Impact factor: 79.321